Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.

Company Data

Name Klotho Neurosciences, Inc. - Common Stock

Company Klotho Neurosciences, Inc.

Symbol KLTO

Website https://klothoneuro.com

Primary Exchange

NASDAQ

ISIN US49876K1034

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Joseph Sinkule

Market Capitalization 44 Mio

Country United States of America

Currency USD

Employees 0,0 T

Address 13576 Walnut Street, 68144 Omaha

ID Changes

Date	From	To
17.09.2024	RWOD	KLTO

Ticker Symbols

Name	Symbol
NASDAQ	KLTO

More Shares

Investors who hold Klotho Neurosciences, Inc. - Common Stock also have the following shares in their portfolio:

ISHARES MSCI AUSTRALIA UCITS ETF USD (ACC) ETF

Kaarya Facilities and Services Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog